Real-world experience with eculizumab in Japanese patients with myasthenia gravis: Post-marketing surveillance data

被引：0
|
作者：
Takahashi, M. [1 ]
Masuda, M. [2 ]
Watanabe, M. [3 ]
Fukamizu, Y. [4 ]
Osawa, T. [4 ]
Kikui, H. [4 ]
Murai, H. [5 ]
机构：
[1] Osaka Univ, Dept Neurol, Grad Sch Med, Osaka, Japan
[2] Tokyo Med Univ, Dept Neurol, Tokyo, Japan
[3] Kyushu Univ, Neurol Inst, Grad Sch Med Sci, Dept Neurol, Fukuoka, Japan
[4] Alex Pharma GK, AstraZeneca Rare Dis, Tokyo, Japan
[5] Int Univ Hlth & Welf, Dept Neurol, Narita, Japan
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-396
引用
收藏
页码：574 / 574
页数：1
相关论文
共 50 条
  • [21] A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data
    Du, Yikuan
    Zhang, Mengting
    Wang, Zhenjie
    Hu, Mianda
    Xie, Dongxia
    Wang, Xiuzhu
    Guo, Zhuoming
    Zhu, Jinfeng
    Zhang, Weichui
    Luo, Ziyi
    Yang, Chun
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (10) : 1422 - 1433
  • [22] A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
    Zhang, Qilin
    Ding, Yiling
    Shu, Yamin
    Chen, Jing
    BMC CANCER, 2023, 23 (01)
  • [23] A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
    Qilin Zhang
    Yiling Ding
    Yamin Shu
    Jing Chen
    BMC Cancer, 23
  • [24] Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study
    Jin, Lei
    He, Dingxian
    Zeng, Quantao
    Tan, Song
    Shi, Jianquan
    Liu, Ying
    Zou, Zhangyu
    Song, Jie
    Yan, Chong
    Huan, Xiao
    Wang, Yuan
    Yang, Lei
    Xi, Jianying
    Wu, Zongtai
    Liu, Ziqi
    Zheng, Jianming
    Zhao, Chongbo
    Chu, Xianglin
    Luo, Sushan
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [25] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [26] All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
    Mana Kobayashi
    Yutaro Kageyama
    Takashi Ando
    Junko Sakamoto
    Shohji Kimura
    Clinical and Experimental Nephrology, 2021, 25 : 854 - 864
  • [27] All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome
    Kobayashi, Mana
    Kageyama, Yutaro
    Ando, Takashi
    Sakamoto, Junko
    Kimura, Shohji
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (08) : 854 - 864
  • [28] Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
    Kim, Hyeongyeong
    Kim, Youngdoe
    Lee, YoungJa
    RHEUMATOLOGY AND THERAPY, 2021, 8 (03) : 1393 - 1404
  • [29] Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
    Hyeongyeong Kim
    Youngdoe Kim
    YoungJa Lee
    Rheumatology and Therapy, 2021, 8 : 1393 - 1404
  • [30] Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
    Nakamura, S.
    Asano, T.
    Tanaka, Y.
    Sugimoto, K.
    Yoshigoe, S.
    Suzuki, Y.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I439 - I441
12345